Treatment for Fibrous Dysplasia: RANKL and Beyond – Dr. Xuefeng Zhao
Dr. Xuefeng Zhao , an orthodontist with a background in bone remodeling, discussed their involvement in fibrous dysplasia (FD) research. He introduced a transgenic mouse model of FD and explored the use of a rank inhibitor as a potential treatment.
The inhibitor showed promising results, reducing osteoclast numbers without affecting FD-initiating cells. In the mouse model, it led to decreased swelling, improved bone volume, and increased bone mineral density. Safety studies are ongoing, and the inhibitor demonstrated a recurrence of FD upon discontinuation due to the presence of initiating cells.
The FD/MAS Alliance Community Conference combined patient-centered science and real-world strategies for patients and families living with fibrous dysplasia, McCune-Albright syndrome (FD/MAS).
The FD/MAS Alliance (formerly Fibrous Dysplasia Foundation) is a community-driven 501c3 nonprofit that fosters the development of evidence-based treatments for Fibrous Dysplasia and McCune-Albright syndrome (FD/MAS). We advance research, provide education and channel the voices of individuals and caregivers with FD/MAS. To support our work visit www.fdmasalliance.org/donate